Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.8 USD | +2.33% | +2.93% | -20.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.18% | 19.33B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B | |
-9.14% | 11.06B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023